NCT00193687

CompletedPhase 3

Bifeprunox in the Treatment of Schizophrenia

Solvay Pharmaceuticals Source

Compare

Other study identifiers

Sponsor study identifier

S154.3.002

Study Type

interventional

Actual enrollment (reported)

986

Locations

0 countries

Sites

N/A

Timeline

Study Start

September 2005

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

January 2008

Actual (reported)

Study Completion

January 2008

Actual (reported)

Brief Summary

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 986 participants
Study completion date: January 2008
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
September 2005
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 11, 2005
Actual (reported)
First Posted
September 19, 2005
Actual (reported)
Primary Completion
January 2008
Actual (reported)
Study Completion
January 2008
Actual (reported)

Last Updated: March 24, 2008
Status Verified: March 2008
Last Update Submitted: March 20, 2008

Conditions

Schizophrenia

Keywords

open-label study in the treatment of schizophrenia

Interventions

bifeprunoxDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

diagnosis of schizophrenia, understand nature of study, able to be managed in out-patient setting for long-term bifeprunox treatment

You may not qualify if:

Sponsors & Collaborators

Solvay Pharmaceuticals
Industrylead

MeSH Terms

Conditions

Schizophrenia

Interventions

bifeprunox

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

Global Clinical Director Solvay
Solvay Pharmaceuticals
STUDY DIRECTOR

Enrollment

986 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

September 11, 2005

First Posted

September 19, 2005

Study Start

September 2005

Date type not reported

This date has not been verified as actual or estimated.

NCT00230828

Patient-reported Outcomes in the Treatment of Schizophrenia

Phase 3Completed

NCT00396214

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

Phase 3Terminated

NCT00658645

Efficacy of Bifeprunox in Patients With Schizophrenia

Phase 3Terminated

NCT00704509

Efficacy of Bifeprunox in Patients With Schizophrenia

Phase 3Terminated

NCT00366704

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

Phase 3Terminated

NCT00141479

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

Phase 2Completed

current primary diagnosis other than schizophrenia, suicide risk, diagnosis or history of substance abuse, uncontrolled hypertension

Contact the study team to confirm eligibility.

Primary Completion

January 2008

Actual (reported)

Study Completion

January 2008

Actual (reported)

Last Updated

March 24, 2008

Record last verified: 2008-03

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00193687
Data provider: ClinicalTrials.gov
Source updated: 2008-03-24
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:30:11 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record